AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication

Written by Kirsten Ruehl on 23rd August 2023. Posted in Client News.

• Previous
• Next